These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 30320198)
1. Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. Tahseen AI; Patel NB JAAD Case Rep; 2018 Oct; 4(9):930-933. PubMed ID: 30320198 [No Abstract] [Full Text] [Related]
2. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. Poduje S; Brozić JM; Prkačin I; Delaš Aždajić M; Goren A Dermatol Ther; 2020 Jan; 33(1):e13174. PubMed ID: 31750971 [TBL] [Abstract][Full Text] [Related]
4. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030 [TBL] [Abstract][Full Text] [Related]
5. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941 [TBL] [Abstract][Full Text] [Related]
6. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Daud A; Gill J; Kamra S; Chen L; Ahuja A J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762 [TBL] [Abstract][Full Text] [Related]
7. The Role of NLRP3 Inflammasome in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Shekhar M; Iqbal O; Dharan A; El-Khateeb H; Jatavallabhula K; Bu P; Bouchard C Med Res Arch; 2024 Jan; 12(1):. PubMed ID: 39026932 [TBL] [Abstract][Full Text] [Related]
8. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164 [TBL] [Abstract][Full Text] [Related]
9. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system. Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience. Çekiç Ş; Canıtez Y; Sapan N Turk Pediatri Ars; 2016 Sep; 51(3):152-158. PubMed ID: 27738400 [TBL] [Abstract][Full Text] [Related]
11. [Vemurafenib-induced toxic epidermal necrolysis]. Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957 [TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729 [TBL] [Abstract][Full Text] [Related]
13. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Tang YH; Mockenhaupt M; Henry A; Bounoua M; Naldi L; Le Gouvello S; Bensussan A; Roujeau JC Clin Exp Allergy; 2012 Feb; 42(2):248-54. PubMed ID: 22092454 [TBL] [Abstract][Full Text] [Related]
14. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis. Ririe MR; Blaylock RC; Morris SE; Jung JY J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282 [TBL] [Abstract][Full Text] [Related]
15. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC; Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739 [TBL] [Abstract][Full Text] [Related]
16. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report. Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493 [TBL] [Abstract][Full Text] [Related]